FFilingSight

CVS Health Corp. (CVS) 10-K Red Flags

Risk signals extracted deterministically from CVS Health Corp.’s SEC 10-K/10-Q XBRL filings — no LLM, every finding cites the underlying data.

Detected red flags (16)

  • Earnings-cash flow divergence: Net income grew +93.6% while operating cash flow declined -17.0%. This divergence may indicate accrual-based earnings inflation — non-cash gains, aggressive revenue recognition, or working capital absorption. The accrual ratio (NI − OCF) is deteriorating.
  • Free cash flow deteriorating: FCF declined +22.7% YoY (from $13.45B to $10.39B). With OCF at $13.43B and capex at $3.03B, cash generation capacity is weakening — monitor for dividend/buyback sustainability.
  • NEW: Going concern doubt in latest filing: The term "going concern" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 16 filing(s).
  • Material weakness in internal controls: The term "material weakness" appears in 19 recent filing(s) (vs 2 in the prior period). This risk language is ongoing.
  • NEW: Restatement of financial statements in latest filing: The term "restate" "financial statements" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 1 filing(s).
  • Operating cash flow exceeds net income: OCF is 1.61x net income, indicating high earnings quality — cash conversion is strong and accruals are not inflating reported profits.
  • Endogenous analysis: Free cash flow declined despite stable or rising capex, indicating the cash burn is operational rather than investment-driven. This is a structural concern — cost reduction or asset sales may be needed to restore FCF.
  • Endogenous analysis: The combination of explicit "going concern" language in the filing with deteriorating cash flow or rising leverage is a severe warning signal — the company's own auditors have flagged doubt about the ability to continue as a going concern.
  • Endogenous analysis: "Material weakness in internal controls" combined with earnings-cash flow divergence is especially concerning — it suggests the reported earnings may not be reliable due to control deficiencies, and the cash flow shortfall may be masking underlying issues.
  • 20 disclosure(s) dropped from prior year — reduced reporting granularity.
  • 3 new risk-language term(s) detected in filing text: Going concern doubt, Restatement of financial statements, Off-balance sheet arrangements.
  • Ongoing high-severity risk language: Material weakness in internal controls.
  • Composite risk: Elevated.
  • Leverage debt/equity 0.89 (moderate).
  • Earnings-cash flow divergence: Net income grew +93.6% while operating cash flow declined -17.0%. This divergence may indicate accrual-based earnings inflation — non-cash gains, aggressive revenue recognition, or working capital absorption. The accrual ratio (NI − OCF) is deteriorating.
  • Free cash flow deteriorating: FCF declined +22.7% YoY (from $13.45B to $10.39B). With OCF at $13.43B and capex at $3.03B, cash generation capacity is weakening — monitor for dividend/buyback sustainability.

Filings & ownership

  • Latest annual report (10-K) filed Feb 10, 2026.
  • Latest quarterly report (10-Q) filed May 6, 2026.
  • 13 recent 8-K material-event filings in the index.
  • Recent insider Form 4s: 0 buy vs 7 sell transactions — net selling $317.5M.
  • ~10,000+ recent 13F-HR filings reference CVS Health Corp.; broad institutional reporting.
  • Recent filers include Modern Wealth Management, LLC, Concorde Asset Management, LLC, Axiom Investment Management LLC.
  • 15 recent 13G passive institutional ownership notices.

Full CVS analyst report

Valuation (DCF & Graham), technicals, macro exposure, risk scorecard and 13F/13D ownership.

View full report →

Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.